Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent and Bolt Partner to Develop Novel Antibody Conjugate Drugs

publication date: Aug 27, 2021

Suzhou Innovent Bio and San Francisco's Bolt Bio will partner to discover three immune-stimulating antibody conjugate (ISAC) candidates for cancer. The conjugate molecules will combine antibody targeting with the power of the innate and adaptive immune systems. Innovent will apply its discovery capability on undisclosed oncology targets. while Bolt will add its ISAC technology and myeloid biology expertise to initiate a new class of immuno-oncology agents. Bolt will receive an upfront payment of $5 million and is eligible for a $10 million equity investment. More details....

Stock Symbols: (HK: 01801) (NSDQ: BOLT)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.